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Abstract
Background: Celastrol is a novel anti-tumor agent. Ways to further enhance this effect of celastrol has attracted
much research attention.
Methods and Results: Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell
line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it
further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite
effects. Celastrol’s miR-223 induction might be due to NF-κB inhibition and transient mTOR activation: these two
events occurred prior to miR-223 elevation in celastrol-treated cells. NF-κB inhibitor, like celastrol, could induce
miR-223; the induction of miR-223 by NF-κB inhibitor or celastrol was reduced by the use of mTOR inhibitor. Finally
and interestingly, miR-223 also could affect NF-κB and mTOR and the effects were different between cells treated or
not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular
viability in the presence of celastrol or not.
Conclusions: For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells,
and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus
provide a novel way to increase celastrol’s anti-cancer effects.
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Background
Celastrol is a natural compound extracted from the plant
triperygium wilfordii Hook F, which has been used in anti-
inflammation and anti-cancer treatments in Chinese folk
medicine for many years. Celastrol has proven effective in
treating a variety of cancers [1], including those arising
from breast [2, 3], prostate [4], lung [5], liver [6], digestive
tract [7], skin [8], and leukemia cells [9], among others.
Celastrol is a promising anti-cancer agent and has
attracted the attention of researchers.
It is commonly accepted that cancer cells surviving
chemotherapy will become resistant to re-use of the
same drugs and cause cancer relapse. It follows that
improving the effects of anti-cancer agents could reduce
or delay cancer re-occurrence. In line with this notion,
we and others have worked on new ways to enhance
celastrol’s anti-cancer effects, especially by focusing on
heat shock response (HSR). Celastrol has been found to
induce heat shock response in multiple cancer cell lines
because of its activation of heat shock factor-1 (HSF-1)
[10]. For example, Matokanovic et al. used siRNA to re-
duce HSP70 levels, thus increasing celastrol’s anti-cancer
ability [11]. Our research found that a peptide deformy-
lase inhibitor, actinonin, could reduce celastrol-induced
HSP70 and increase celastrol’s anti-proliferation effects
[12]. It is reasonable to think that there might be other
treatment-caused responses that affect celastrol’s anti-
cancer effects. To identify these might provide a new
way to enhance celastrol’s role as an anti-cancer agent.
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It has been reported that miR-223 influences the survival
ability of various cancer cells [13]. Yang et al. found that
miR-223 promoted the invasion of breast cancer cells via
the Mef2c-β-catenin pathway [14], while Pinatel et al. re-
ported that overexpressing miR-223 decreased migration,
increased cell death in anoikis conditions and augmented
sensitivity to chemotherapy, but had no effect on adhesion
and proliferation [15]. miR-223 is also reported to promote
the biological behavior of prostate cancer [16], contribute
to gastric cancer cell proliferation and migration [17], and
function as an oncogene in human colorectal cancer cells
[18]. Recently, we found that celastrol could induce miR-
223 in human hepatoma cells (unpublished).
Therefore, whether or not celastrol-caused miR-223
elevation affects celastrol’s anti-cancer action, and if so,
why, are questions worth addressing. To do so, we first
observed miR-223 alterations caused by celastrol in hu-
man breast cancer line MCF-7 and prostate cancer line
PC3 (two of the most common types of cancer and the
two cancer types most often used in celastrol studies), as
well as the effects of manipulating miR-223 on celastrol’s
ability to reduce the number of living cells. Then, we
investigated the possible reason for celastrol’s miR-223
induction by focusing on how altering NF-κB affects
miR-223 expression, since celastrol is a known NF-κB
regulator [19–21], and NF-κB reportedly regulates miR-
223 [22]. In addition, in pre-experimental trials, we
found that NF-κB activity affected and was linked to
mTOR activity and HSP70 levels. Therefore, the effects
of altering mTOR and HSP70 on miR-223 expression
were also investigated. Finally, we tried to find the possible
molecular basis by which miR-223 alterations affected cel-
lular viability in cells treated or not treated with celastrol.
Again, we focused on NF-κB, mTOR, and HSP70, since
these three molecules are widely reported as related to
celastrol’s anti-tumor effects [10, 23–26]. Importantly,
miR-223 could regulate NF-κB [27], mTOR [28, 29], and
members of the heat shock protein family [28].
Methods
Reagents and drugs
Dimethyl sulfoxide (DMSO) was purchased from Sigma
(St. Louis, MO). NF-κB inhibitor (PDTC) and mTOR
inhibitor (Ku-0063794) were obtained from Roche
(Mannheim, Germany). Carboxyfluorescein diacetate,
succinimidyle ester (CFSE) was from Molecular Probe
(Eugene, OR) and 7-Amino-actinomycin D (7-AAD)
was purchased from Anaspec (San Jose, CA). Protein
Extraction Kit, BCA protein assay reagent kit and Beyo
ECL Plus for western blot were purchased from Beyo-
time Biotechnology (Jiangsu, China). Anti-phospho-
HSF-1 (Ser326), anti-phospho-mTOR (Ser2481), and
anti-mTOR were purchased from Epitomics (CA).
Anti-β-action, anti-HSP70, anti-phospho-NF-κB (Ser536)
and horseradish peroxidase (HRP)-labeled secondary anti-
bodies were purchased from Cell Signaling Technology
(MA).
Celastrol was extracted as previously reported by us
[30, 31]: briefly, the air-dried root bark of triperygium
wilfordii Hook F (from Fujian Province, China) was pow-
dered and extracted in refluxing n-hexane, the extract was
chromatographed on silica gel and eluted with gradient n-
hexane/acetone. The celastrol-containing fraction (red
color) was collected, evaporated, and recrystallized with
acetone to produce celastrol (needle red crystal). The pur-
ity of the obtained celastrol was over 99.0 %, as determined
by high-performance liquid chromatography (Agilent 1200,
Santa Clara, CA; celastrol standard was from Sigma). The
celastrol was dissolved in DMSO at 50 mM. The celastrol
solution was stored at -20 °C and used within 3 months of
preparation. The stored solution was further diluted with
RPMI 1640 medium or DMEM to a proper lower concen-
tration immediately prior to experiments.
Cell culture and treatment by Celastrol, PDTC and
Ku-0063794
Breast cancer cell line MCF-7, prostate cancer cell line
PC3 and leukemic cell lines U937 used in this study
were all obtained from the Shanghai Cell Bank of the
Chinese Academy of Sciences (Shanghai, China). Cells
were maintained in RPMI 1640 or DMEM supplemented
with 10 % FBS, 100 IU/ml penicillin and 100 μg/ml
streptomycin (all from PAA Laboratories, Linz, Austria),
and cultured in a humidified 5 % CO2 atmosphere in an
incubator at 37 °C. Exponentially growing cells were
used for experiments. Cells were seeded into 24-well
(2 × 105 cells) or 6-well (8 × 105 cells) culture plates
followed by exposure to the indicated doses of celas-
trol, or PDTC (20 μM), or Ku-0063794 (3 μM) or the
combination of these agents for the indicated times. The
culture medium with DMSO (vehicle) served as control.
Each experiment was repeated at least three times.
Cell transfection
2 × 105 cells were seeded in 24-well plates or 8 × 105 cells
were seeded in 6-well plates for 1 day before transfection.
MiR-223-Down antagomir, miR-223 mimics, or siRNA for
HSP70 gene or their controls were transfected into cells
by siRNA-mate (GenePharma Shanghai, China), according
to the manufacturer recommendations. The transfection
was terminated by PBS washing after 24 h and the cells
were used for subsequent experiments as indicated.
Cell counting by flow cytometry (FCM)
After receiving different treatments, cells were collected
and washed with PBS. Cell numbers were accurately quan-
tified by flow cytometry, based on a single-tube platform
with self-made cell-beads as internal controls, a method
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originally reported by Harrison et al. [32] and modified by
us [33]. Briefly, samples were collected and then a known
number of self-made CFSE-containing cell-beads added.
The cell-beads contained green fluorescence, made by in-
cubation of U937 cells with CFSE. Before analysis by
FACScalibur flow cytometer (Becton-Dickinson, CA), 7-
AAD was added with a final concentration of 1 μg/ml for
separating dead cells. The number of vital (or dead) cells
was calculated using the following equation:
Number of vital deadð Þ cells
¼ ½number of vital deadð Þ cells detected=
number of cell‐beads detected
 number of cell‐beads input
RNA isolation and Quantitative real-time PCR (qRT - PCR)
Total RNA was extracted from MCF-7 and PC3 cells
using an RNA extraction kit (Fastagen Biotechnology,
Shanghai, China) according to the manufacturer’s proto-
cols. One microgram of total RNA was reverse tran-
scribed, using the ReverTra Ace qPCR-RT Master mix kit
(Toyobo, Qsaka,Japan) and reverse-transcription primers
specific to the miRNAs of interest (GenePharma).
The reaction was performed on Applied Biosystems
(CA), at 37 °C for 15 min, 50 °C for 5 min, 98 °C for
5 min, and stopped at 4 °C. The obtained miRNA-
specific cDNA was amplified on an Agilent MX3000P
machine (CA), using the Realtime PCR master mix
(Toyobo); with processing at 95 °C for 30 s, followed
by 40 cycles at 95 °C for 5 s, 55 °C for 5 s, and 72 °C for
30 s. U6 small nuclear RNA was used as an endogenous
control. The fold change in the level of detected miRNA
was calculated using the following equation:
ΔCt ¼ Ct miRNA – Ct U6
Relative Expression Ratio ¼ 2‐ΔCt
Western blot
MCF-7 and PC3 cells were incubated in lysis buffer and
cleared by centrifugation at 13,000 × g for 15 min. The
extraction of cytoplasmic and nuclear protein was per-
formed according to product manufacturer instructions.
The BCA protein assay reagent kit determined protein
concentrations. Proteins were separated by 10 % SDS-
polyacrylamide gels and then transferred to polyvinylide-
nedifluoride (PVDF) membranes (Millipore, Bedford,
MA). Membranes were probed with antibodies against
the proteins of interest. Detection was accomplished
using corresponding HRP-conjugated secondary anti-
bodies followed by development with Beyo ECL Plus.
Pictures were captured and band densities measured by
G: BOX iChemi XR (Syngene Inc., UK).
Statistical analysis
All experiments were repeated at least three times. Data
are presented as the mean ± SD. The data from multiple
groups were analyzed with a one-way analysis of vari-
ance. Data from two groups were compared by t-tests. A
value of P < 0.05 was considered significant.
Results
Celastrol reduced viable cells and induced miR-223
expression in MCF-7 and PC3 in time- and dose-dependent
ways
We first observed the dose-effects of celastrol on the
number of living cells in human breast cancer cell line
MCF-7 and prostate cancer cell line PC3. As shown in
Fig. 1a, celastrol treatment for 24 h reduced viable cells
in MCF-7 and PC3, the IC50 for MCF-7 and PC3 cells
were about 4 μM and 2 μM, respectively (Fig. 1a), these
doses were used for the two cell lines for most of the
following experiments.
We found that after 6 h treatment, celastrol could
significantly induce miR-223 expression in the two
cell lines. MCF-7’s response was more pronounced
than the PC3 response. Celastrol-caused induction still
existed at 24 h. miR-223 induction was dose-dependent
in that higher dosages resulted in higher miR-223 levels
(Fig. 1b).
Down-regulating or overexpressing miR-223 increased or
decreased the loss of viable cells in celastrol-treated
samples, respectively
Since celastrol could induce miR-223 expression, and
this small RNA is reported to affect the viability of can-
cer cells, including MCF-7 and PC3 [13–16], we were
interested in whether regulating miR-223 levels affected
celastrol’s anti-cancer ability. To address this issue, we
inhibited or over-expressed miR-223 and observed the
effects of such manipulation on celastrol’s action.
After 24 h transfection with miR-223-Down antagomir
or miR-223 mimics, miR-223 was inhibited or elevated,
respectively (Fig. 2a). The results of culture-transfected
cells after 60 h showed that down-regulating or overex-
pressing miR-223 alone could increase or decrease viable
cells in MCF-7 and PC3 when compared to controls
(mock transfection) (Fig. 2b, c). However, cells receiving
miR-223-Down antagomir transfection had lower num-
bers of viable cells in the presence of celastrol, when
compared to those without transfection or mock trans-
fection (Fig. 2b). On the contrary, cells with miR-223
mimic transfection reduced the loss of viable cells in
presence of celastrol, when compared to no transfection
or mock transfection (Fig. 2c). These results indicate
that blocking miR-223 elevation could further reduce liv-
ing cells in samples treated with celastrol.
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Celastrol affected mTOR, NF-κB, and HSF-1 activation
before inducing miR-223
We were then interested in why celastrol could induce
miR-223. Since celastrol is a strong NF-κB regulator
[19–21], and NF-κB reportedly regulates miR-223 [22],
we thought that regulating NF-κB might be involved in
miR-223 induction. Additionally, our pre-experimental
trial showed that changing NF-κB could result in, and
was thus linked to alterations in mTOR activity and
HSP70 levels in MCF-7 and PC3 (data not shown).
These two molecules might also play roles in celastrol’s
miR-223 regulation. Nevertheless, if a molecular alter-
ation is the cause behind celastrol’s miR-223 induction,
it should meet two requirements, (1) following celastrol
treatment, this alteration must happen before miR-223
induction and (2) this alteration itself could regulate
miR-223 in our system.
Therefore, we first observed whether celastrol-caused
alterations in NF-κB, mTOR and HSP70 occurred, and if
they preceded miR-223 elevation (which were obvious at
6 h after celastrol treatment). As shown in Fig. 3a, re-
ductions in NF-κB phosphorylation, indicating NF-κB
inhibition, were seen as early as 5 min after celastrol
addition. This change remained at least to 6 h, the end
point of observations in our study. At 5 min after celastrol
loading, mTOR phosphorylation was increased, indicating
the cells had increased mTOR activation; however, by 1 h
after celastrol treatment, mTOR activation began to be
inhibited (Fig. 3a). Celastrol-caused mTOR inhibition has
been reported [23, 26], yet, for the first time we found that
prior to inhibition there was an early and transient in-
crease in mTOR activation. HSF-1 activations were seen
at 10 min after celastrol treatment (Fig. 3a). HSF-1 activa-
tion is reported as important to celastrol-caused heat
shock response, a hallmark of which is HSP70 elevation
[10]. In agreement with such findings, HSP70 elevation
was observed at 6 h after celastrol addition (Fig. 3b), a
time-point coinciding with miR-223 elevation (Fig. 1b).
These alterations in mTOR, NF-κB, and HSF-1 activation,
as well as HSP70 induction, were not only time-dependent,
but also dose-dependent, in that higher doses prompted
stronger responses.
The above data shows that, NF-κB inhibition and tran-
sient mTOR activation, but not HSP70 elevation, oc-
curred before miR-223 elevation and thus might be the
cause of miR-223 elevation in celastrol-treated cells.
Inducing miR-223 by celastrol was related to NF-κB
inhibition and mTOR activation
Then, we observed the effects of altering NF-κB or
mTOR activity on miR-223 expression. We found that
NF-κB inhibitor could induce miR-223, while mTOR
inhibitor down-regulated miR-223 (Fig. 4a). When the
two inhibitors were used together, miR-223 elevation
was inhibited (Fig. 4a). mTOR inhibitor also reduced
celastrol-caused miR-223 elevation (Fig. 4b). This sug-
gests that mTOR activation was necessary for miR-
223 induction. To evidence this notion, we found that
the NF-κB inhibitor that elevated miR-223 could also
increase mTOR activation (Fig. 4a). These findings
suggest that celastrol’s miR-223 induction was related
to NF-κB inhibition and transient mTOR activation
(as shown in Fig. 3a).
We also used siRNA transfection to knock down
HSP70 and found that the cells with lowered HSP70
had decreased miR-223 (data not shown), suggesting
that celastrol-induced HSP70 elevation might contrib-
ute to miR-223 maintenance, though this effect would
occur at a later stage, such as more than 6 h after
celastrol treatment.
Fig. 1 Effects of celastrol on number of living cells and miR-223 in two cell lines. a Celastrol’s effects on viable cell numbers. MCF-7 or PC3 cells
were cultured with different doses of celastrol (with solvent DMSO as control) for 24 h. Then the number of viable cells was quantified by flow
cytometry with one-platform protocol, as detailed in Methods. b Inducing miR-223 with celastrol. After incubation with celastrol at the indicated
doses for the indicated time, the cells’ total RNA was extracted and reverse transcription was performed. Then miR-223 levels were determined by
quantitative PCR with specific primers. Cel represents celastrol. The tests were repeated three times. Data is presented as mean ± SD; statistics were
determined between the celastrol-treated group and DMSO, * indicates P < 0.05, while ** indicates P < 0.01
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miR-223 affected cellular viability-related NF-κB, mTOR
activity, and HSP70 level
The final step in this work was to try to find the possible
molecular basis for miR-223’s effects on cellular viability
in samples treated or not treated with celastrol. Again,
we focused on the relationship between miR-223 and
NF-κB, mTOR, and HSP70, but in reverse. That is to
say, we looked into the possible effects of miR-223 on
these molecules, since these molecules, as mentioned
above, reportedly affect celastrol’s anti-tumor ability, and
also because miR-223 has been confirmed as regulating
these molecules [27–29]. If a molecular alteration is in
fact the basis for miR-223’s effects on celastrol’s ability
to reduce viable cells, this molecular alteration should
affect cellular viability in cells treated with celastrol in
addition to being regulated by miR-223 alterations.
We therefore first observed the effects of NF-κB,
mTOR, or HSP70 activation on cell viability. As shown
in Fig. 5a, knocking down HSP70 or use of either NF-κB
or mTOR inhibitor alone could reduce the numbers of
viable cells in MCF-7 or PC3. In samples treated by
celastrol, any one of these manipulations could reduce
the number of living cells further. Thus, NF-κB and
mTOR activation, as well as HSP70 elevation, were
Fig. 2 Effects of regulating miR-223 on viable cell numbers. a Regulating miR-223 by transfection. Cells were transfected with miR-223-Down
antagomir (shortened to anti-miR-223) or miR-223 mimics or corresponding mock agent (mock transfection) for 24 h, then the miR-223 levels
were determined by PCR to confirm if transfection was successful. b and c miR-223’s effects on viable cell numbers. After cells were transfected
with anti-miR-223 (b) or miR-223 mimics (c) for 24 h, the cells were washed with PBS and then cultured with celastrol at different doses or with
DMSO for 60 h. Cell numbers were determined by flow cytometry. Tests were repeated three times, data is presented as mean ± SD,
statistics were determined between specific transfection and mock transfection, or as demonstrated in figures. * indicates P < 0.05, while ** and
*** indicate P < 0.01 and P < 0.001, respectively
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important for cellular survival in samples treated or not
by celastrol.
We then observed the effects of miR-223 on NF-κB,
mTOR and HSP70 in cells treated or not by celastrol.
As shown in Fig. 5b, down-regulating miR-223 alone
could activate NF-κB (in favor of survival), yet inhibited
mTOR and HSF-1 activity and decreased HSP70 level
(prone to reducing survival). These effects are contrary,
but perhaps the effects of NF-κB alteration are dominant
(a hypothesis adjusted in the Discussion section), making
the final outcome of miR-223 down-regulation an in-
crease in viable cells (as presented in above Fig. 2b). The
observed decrease in viable cells from up-regulating
miR-223 (Fig. 2b) is also explainable through NF-κB
dominance: this manipulation inhibits NF-κB while acti-
vating mTOR and HSF-1 and elevating HSP70 (Fig. 5b).
Fig. 3 Celastrol’s effects on multiple molecules. MCF-7 or PC3 cells were treated with different concentrations of celastrol for the indicated time,
and phosphorylated NF-κB (p-NF-κB), p-mTOR, and p-HSF-1 (panel a), as well as total HSP70 (panel b), were detected by Western blot with the
corresponding antibody. The band density was measured, and the density of specific proteins of one sample was adjusted by the density
of β-actin in the same sample. The relative expression of one protein of interest (X) in the test sample was found by the algorithm:
(adjusted density of X in test sample)/(adjusted density of X in control sample), with the relative expression of X protein in the control
set as 1. The mean of relative expressions of all specific proteins in different treatments is displayed by heat map, which was created by
ggplot2 package of R language (https://www.r-project.org/). The experiments were repeated three times
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Interestingly and strangely, the above data showed that
miR-223 down-regulation could activate NF-κB in cells
not treated with celastrol, however, when celastrol was
used, cells with knocked-down miR-223 showed lower
NF-κB and mTOR activity than cells with mock trans-
fection. This indicates that down-regulating miR-223 en-
hanced celastrol-caused NF-κB and mTOR activity
inhibition (both prone to reducing survival) (Fig. 5b).
This provides an explanation for the finding that miR-
223 down-regulation increased loss of living cells in
celastrol-treated samples (Fig. 2b), rather than promot-
ing survival, as when celastrol was not used (Fig. 2b).
Up-regulating miR-223 ameliorated celastrol-caused NF-
κB and mTOR inhibition (Fig. 5b), a finding consistent
with the result that miR-223 overexpression reduced the
loss of living cells in celastrol-treated samples (Fig. 2b).
Altering miR-223, however, showed inconsistent effects
on celastrol-induced HSP70 elevation in the two cell
lines (Fig. 5b).
Discussion
In this work, we found that both non-toxic and toxic
doses of celastrol could induce miR-223 expression in hu-
man cancer cell lines MCF-7 and PC3, and that miR-223
down-regulation further reduced the number of living
cells in these two cancer lines treated by celastrol.
One interesting finding of our work is that celastrol
could induce miR-223 in MCF-1 and PC3. Such an ac-
tion was significant at 6 h after celastrol loading, and the
effect increased with dose. Results were cell-context
dependent, as MCF-7 showed a stronger response than
PC3. To support that celastrol might affect microRNA,
it was recently reported that celastrol decreased miR-
224 and miR-21 [7, 34]. Celastrol’s induction of miR-223
helps to explain the mechanisms behind some of celas-
trol’s other known actions, such as celastrol’s newly
identified potential in anti-obesity applications, since
miR-223 is not only a major regulator of cholesterol
(miR-223 can reduce cholesterol) [35], but also an insu-
lin sensitivity enhancer [36]. miR-223 induction is also
consistent with celastrol’s efficacy in anti-inflammation
applications [37, 38].
Another finding is that miR-223 affected celastrol’s
ability to reduce numbers of viable cancer cells. We
confirmed that when miR-223 was inhibited in MCF-7
and PC3 cells treated by celastrol, the numbers of living
cells could be further reduced, while down-regulating
miR-223 alone increased the number of living cells.
Over-expression of miR-223 had the opposite effect
on viable cell numbers when compared to miR-223 down-
regulation, either when used alone or when in combin-
ation with celastrol. Celastrol’s anti-proliferation effects
were less pronounced in MCF-7 than PC3. This difference
may be attributed to MCF-7’s higher miR-223 levels in-
duced by celastrol. The effects of miR-223 on breast can-
cer are harder to explain due to inconsistent research
data, with some studies showing promoting effects and
others showing suppression [14, 15]. The reason for this
discrepancy requires further investigation. Wei et al. re-
cently reported that miR-223 promoted prostate cancer
behavior [16], yet this was different from our results. One
explanation for the difference is that they did not wash
away the transfection reagents when performing their ana-
lysis, while we did. Transfection reagents are often toxic
Fig. 4 Effects of NF-κB and/or mTOR acidity on miR-223 expression. a Effects of NF-κB inhibitor and/or mTOR inhibitor on miR-223. MCF-7 or PC3
cells were treated with NF-κB inhibitor (PDTC) and/or mTOR inhibitor Ku-0063794 (abbreviated as Ku) for 1 or 6 h, then, the RNA (6 h samples)
was extracted and miR-223 determined by quantitative reverse-transcription PCR. Protein (for 1 h) was extracted and phosphorylated NF-κB and
mTOR were determined by Western blot. b Effects of mTOR inhibitor on celastrol-induced miR-223 expression. Cells were treated with celastrol
and/or mTOR inhibitor for 6 h, then the miR-223 was detected. Cel represents celastrol. Tests were repeated three times. Data are presented as
mean ± SD; * indicates P < 0.05, while ** indicates P < 0.01
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Fig. 5 (See legend on next page.)
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to cells, and might affect outcomes. Indeed, celastrol
is a toxic agent, and our results showed that in presence
of celastrol, miR-223 overexpression promoted survival.
Nevertheless, our work suggests that simultaneous in-
hibition of miR-223 induction could be a novel way
to increase celastrol’s anti-cancer ability, at least in
breast or prostate cancer.
Third, we found that NF-κB, mTOR, or HSP70 could
regulate miR-223. This offers a possible explanation for
celastrol’s miR-223 induction. Based on the following
facts, we thought that celastrol-induced miR-223 might
be related to NF-κB inhibition and rely on transient
mTOR activation. One: NF-κB inhibition and mTOR ac-
tivation (both observable at 5 min after celastrol treat-
ment, though mTOR was inhibited by 1 h) preceded
miR-223 elevation (at 6 h). Two: like celastrol, NF-κB
inhibitor PDTC could induce miR-223. This effect was
accompanied by mTOR activation. Three: mTOR inhibi-
tor could reduce celastrol- or NF-κB inhibitor-induced
miR-223 elevation. Kumar et al. reported that in combin-
ation with Notch, NF-κB activation, rather than inhibition,
elevated miR-223 [22]. This difference in results might be
cell-type specific. To support this notion, our bioinformat-
ics work with ChIPBase software [39] identified multiple
NF-κB binding sites up- and down-stream of the miR-223
loci in the human X chromosome. Different binding sites
used by NF-κB in different cells might cause varying ef-
fects on miR-223 expression. Down-regulating HSP70 re-
duced miR-223 (data not shown), indicating that celastrol-
induced HSP70 elevation might play a role in maintaining
miR-223 level, through in the later stage after celastrol
treatment, as HSP70 elevation needed 6 h.
Finally and interestingly, in addition to miR-223 being
affected by NF-κB and mTOR activity and HSP70 levels,
miR-223 could regulate these three molecules, providing
a clue to understanding the effects of miR-223 on
cellular viability. In our system, NF-κB- or mTOR-
inhibitor or knocking down HSP70 could reduce vi-
able cells, meaning that these three molecules are all
important to survival. However, the effects of NF-κB
might dominate if the alterations of these molecules
compete, a hypothesis deduced from celastrol’s effects, as
this agent resulted in NF-κB inhibition (reducing survival),
mTOR inhibition, and HSP70 reduction (both increasing
survival), with a final outcome of reduced survival. As
such, NF-κB dominance explains why overexpression of
miR-223 alone reduced viable cells, even when mTOR ac-
tivity and HSP70 levels were increased (because such a
manipulation inhibited NF-κB activity). That miR-223
down-regulation increased viable cell can also be ex-
plained in this way, since it showed the opposite effect on
NF-κB, mTOR, and HSP70. Moreover, the observed facts
that miR-223 over-expression or down-regulation, when
compared with their mock transfections, could reduce or
further increase viable cell loss in celastrol-treated sam-
ples, were understandable: up- or down-regulating miR-
223 could ameliorate or increase celastrol-caused NF-κB
and mTOR inhibition, respectively. miR-223 could regu-
late HSP70 level, yet the effects were inconsistent in two
cell lines as well as in situation with and not with celastrol,
thus making us difficult to relate miR-223’s effects to its
altering HSP70.
Conclusions
Our work discloses that celastrol, in a NF-κB inhibition/
mTOR activation-related way, induces miR-223 in MCF-
7 and PC3, and that down-regulating miR-223 could fur-
ther reduce living cancer cells in samples treated with
celastrol. Inhibiting miR-223 induction, in addition to
blocking heat shock response [11, 12], is novel way to
increase celastrol’s anti-cancer ability.
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Fig. 5 Effects of on multiple molecules on cellular viability and miR-223 regulation of these molecules. a Effects of multiple molecules on cellular
viability. The cells were pre-treated with NF-κB inhibitor (PDTC) or mTOR inhibitor Ku-0063794 (abbreviated as Ku) for 1 h, or transfected with
siRNA specific to hsp70 gene or non-specific siRNA (mock) for 24 h and subsequently washed to stop transfection. Cells were then treated with
celastrol (4 μM for MCF-7 and 2 μM for PC3) or DMSO for 24 h, before the numbers of viable cells were quantified with flow cytometry. b Effects
of miR-223 alteration on multiple molecules. Cells were transfected with miR-223-Down antagomir (shortened to anti-miR-223) or miR-223 mimics
or corresponding mock agent (mock transfection) for 24 h, then the cells were washed to stop transfections. Some of the cells were used immediately
to extract protein; the remaining ones were used for culture with celastrol (4 μM for MCF-7 and 2 μM for PC3) or DMSO for the indicated time, before
proteins were extracted. The obtained proteins were used to detect phosphorylated NF-κB (p-NF-κB), p-mTOR, and p-HSF-1, as well as whole levels of
HSP70 by Western blot, with respective primary antibodies and corresponding secondary antibodies being used. The mean of relative expressions of
specific proteins in different treatments is displayed by heat map (detailed in the legend of Fig. 3). Tests were repeated three times. Cel represents
celastrol. Data in A panel are presented as mean ± SD, statistics were determined between different treatments (without celastrol) and DMSO control,
or between different treatments (plus celastrol) and celastrol alone * indicates P < 0.05, while ** indicates P < 0.01
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